$20.51
3.17% day before yesterday
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US63009J1079
Symbol
NBTX

Nanobiotix - ADR Target price 2025 - Analyst rating & recommendation

Nanobiotix - ADR Classifications & Recommendation:

Buy
92%
Hold
8%

Nanobiotix - ADR Price Target

Target Price $11.98
Price $20.51
Deviation
Number of Estimates 8
8 Analysts have issued a price target Nanobiotix - ADR 2026 . The average Nanobiotix - ADR target price is $11.98. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 11 Analysts recommend Nanobiotix - ADR to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Nanobiotix - ADR stock has an average upside potential 2026 of . Most analysts recommend the Nanobiotix - ADR stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million $ -13.63 28.64
138.61% 310.09%
EBITDA Margin 575.28% -181.32%
789.08% 131.52%
Net Margin 586.94% -145.23%
544.42% 124.74%

6 Analysts have issued a sales forecast Nanobiotix - ADR 2025 . The average Nanobiotix - ADR sales estimate is

$28.6m
Unlock
. This is
310.09% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$41.6m 405.06%
Unlock
, the lowest is
$17.3m 226.64%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $-13.6m 138.61%
2025
$28.6m 310.09%
Unlock
2026
$50.0m 74.67%
Unlock
2027
$93.2m 86.32%
Unlock
2028
$120m 28.37%
Unlock
2029
$120m 0.26%
Unlock
2030
$151m 26.11%
Unlock
2031
$328m 116.79%
Unlock
2032
$669m 103.91%
Unlock

4 Analysts have issued an Nanobiotix - ADR EBITDA forecast 2025. The average Nanobiotix - ADR EBITDA estimate is

$-51.9m
Unlock
. This is
33.78% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-39.1m 50.15%
Unlock
, the lowest is
$-63.3m 19.28%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-78.4m 166.07%
2025
$-51.9m 33.78%
Unlock
2026
$-13.7m 73.59%
Unlock
2027
$31.8m 331.88%
Unlock
2028
$-78.2m 345.99%
Unlock

EBITDA Margin

2024 575.28% 789.08%
2025
-181.32% 131.52%
Unlock
2026
-27.42% 84.88%
Unlock
2027
34.12% 224.43%
Unlock

7 Nanobiotix - ADR Analysts have issued a net profit forecast 2025. The average Nanobiotix - ADR net profit estimate is

$-41.6m
Unlock
. This is
48.01% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-27.5m 65.66%
Unlock
, the lowest is
$-49.1m 38.64%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-80.0m 71.60%
2025
$-41.6m 48.01%
Unlock
2026
$-15.3m 63.14%
Unlock
2027
$10.4m 167.91%
Unlock
2028
$33.6m 222.77%
Unlock
2029
$68.0m 102.32%
Unlock
2030
$101m 47.97%
Unlock

Net Margin

2024 586.94% 544.42%
2025
-145.23% 124.74%
Unlock
2026
-30.65% 78.90%
Unlock
2027
11.17% 136.44%
Unlock
2028
28.09% 151.48%
Unlock
2029
56.68% 101.78%
Unlock
2030
66.51% 17.34%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -1.69 -0.88
34.13% 47.93%
P/E negative
EV/Sales 33.18

7 Analysts have issued a Nanobiotix - ADR forecast for earnings per share. The average Nanobiotix - ADR EPS is

$-0.88
Unlock
. This is
47.93% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.58 65.68%
Unlock
, the lowest is
$-1.04 38.46%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.69 34.13%
2025
$-0.88 47.93%
Unlock
2026
$-0.32 63.64%
Unlock
2027
$0.22 168.75%
Unlock
2028
$0.71 222.73%
Unlock
2029
$1.43 101.41%
Unlock
2030
$2.12 48.25%
Unlock

P/E ratio

Current -12.14 82.16%
2025
-23.38 92.65%
Unlock
2026
-63.42 171.26%
Unlock
2027
93.41 247.29%
Unlock
2028
28.93 69.03%
Unlock
2029
14.30 50.57%
Unlock
2030
9.66 32.45%
Unlock

Based on analysts' sales estimates for 2025, the Nanobiotix - ADR stock is valued at an EV/Sales of

33.18
Unlock
and an P/S ratio of
33.22
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -69.71 1,386.16%
2025
33.18 147.60%
Unlock
2026
19.00 42.75%
Unlock
2027
10.20 46.33%
Unlock
2028
7.94 22.10%
Unlock
2029
7.92 0.25%
Unlock
2030
6.28 20.71%
Unlock
2031
2.90 53.87%
Unlock
2032
1.42 50.96%
Unlock

P/S ratio

Current
2026
19.02 42.75%
Unlock
2027
10.21 46.33%
Unlock
2028
7.95 22.10%
Unlock
2029
7.93 0.25%
Unlock
2030
6.29 20.71%
Unlock
2031
2.90 53.87%
Unlock
2032
1.42 50.96%
Unlock

Current Nanobiotix - ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
PORTZAMPARC BNP PARIBAS
Locked
Locked
Locked Aug 05 2025
ODDO BHF
Locked
Locked
Locked Jun 09 2025
ODDO BHF
Locked
Locked
Locked Jun 08 2025
H.C. WAINWRIGHT & CO., LLC
Locked
Locked
Locked May 27 2025
H.C. WAINWRIGHT & CO., LLC
Locked
Locked
Locked May 26 2025
STIFEL EUROPE
Locked
Locked
Locked May 22 2025
STIFEL EUROPE
Locked
Locked
Locked May 21 2025
Analyst Rating Date
Locked
PORTZAMPARC BNP PARIBAS:
Locked
Locked
Aug 05 2025
Locked
ODDO BHF:
Locked
Locked
Jun 09 2025
Locked
ODDO BHF:
Locked
Locked
Jun 08 2025
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
Locked
May 27 2025
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
Locked
May 26 2025
Locked
STIFEL EUROPE:
Locked
Locked
May 22 2025
Locked
STIFEL EUROPE:
Locked
Locked
May 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today